TY - JOUR
T1 - Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women
AU - Zavala, Valentina A.
AU - Casavilca-Zambrano, Sandro
AU - Navarro-Vásquez, Jeannie
AU - Castañeda, Carlos A.
AU - Valencia, Guillermo
AU - Morante, Zaida
AU - Calderón, Monica
AU - Abugattas, Julio E.
AU - Gómez, Henry
AU - Fuentes, Hugo A.
AU - Liendo-Picoaga, Ruddy
AU - Cotrina, Jose M.
AU - Monge, Claudia
AU - Neciosup, Silvia P.
AU - Huntsman, Scott
AU - Hu, Donglei
AU - Sánchez, Sixto E.
AU - Williams, Michelle A.
AU - Núñez-Marrero, Angel
AU - Godoy, Lenin
AU - Hechmer, Aaron
AU - Olshen, Adam B.
AU - Dutil, Julie
AU - Ziv, Elad
AU - Zabaleta, Jovanny
AU - Gelaye, Bizu
AU - Vásquez, Jule
AU - Gálvez-Nino, Marco
AU - Enriquez-Vera, Daniel
AU - Vidaurre, Tatiana
AU - Fejerman, Laura
N1 - Publisher Copyright:
© 2022 The Authors.
PY - 2022/8
Y1 - 2022/8
N2 - Background: Breast cancer incidence in the United States is lower in Hispanic/Latina (H/L) compared with African American/ Black or Non-Hispanic White women. An Indigenous American breast cancer-protective germline variant (rs140068132) has been reported near the estrogen receptor 1 gene. This study tests the association of rs140068132 and other polymorphisms in the 6q25 region with subtype-specific breast cancer risk in H/Ls of high Indigenous American ancestry. Methods: Genotypes were obtained for 5,094 Peruvian women with (1,755) and without (3,337) breast cancer. Associations between genotype and overall and subtype-specific risk for the protective variant were tested using logistic regression models and conditional analyses, including other risk-associated polymorphisms in the region. Results: We replicated the reported association between rs140068132 and breast cancer risk overall [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.47-0.59], as well as the lower odds of developing hormone receptor negative (HR-) versus HR+ disease (OR, 0.77; 95% CI, 0.61-0.97). Models, including HER2, showed further heterogeneity with reduced odds for HR+HER2+ (OR, 0.68; 95% CI, 0.51-0.92), HR-HER2+ (OR, 0.63; 95% CI, 0.44-0.90) and HR-HER2- (OR, 0.77; 95% CI, 0.56-1.05) compared with HR+HER2-. Inclusion of other risk-associated variants did not change these observations. Conclusions: The rs140068132 polymorphism is associated with decreased risk of breast cancer in Peruvians and is more protective against HR- and HER2+ diseases independently of other breast cancer-associated variants in the 6q25 region. Impact: These results could inform functional analyses to understand the mechanism by which rs140068132-G reduces risk of breast cancer development in a subtype-specific manner. They also illustrate the importance of including diverse individuals in genetic studies.
AB - Background: Breast cancer incidence in the United States is lower in Hispanic/Latina (H/L) compared with African American/ Black or Non-Hispanic White women. An Indigenous American breast cancer-protective germline variant (rs140068132) has been reported near the estrogen receptor 1 gene. This study tests the association of rs140068132 and other polymorphisms in the 6q25 region with subtype-specific breast cancer risk in H/Ls of high Indigenous American ancestry. Methods: Genotypes were obtained for 5,094 Peruvian women with (1,755) and without (3,337) breast cancer. Associations between genotype and overall and subtype-specific risk for the protective variant were tested using logistic regression models and conditional analyses, including other risk-associated polymorphisms in the region. Results: We replicated the reported association between rs140068132 and breast cancer risk overall [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.47-0.59], as well as the lower odds of developing hormone receptor negative (HR-) versus HR+ disease (OR, 0.77; 95% CI, 0.61-0.97). Models, including HER2, showed further heterogeneity with reduced odds for HR+HER2+ (OR, 0.68; 95% CI, 0.51-0.92), HR-HER2+ (OR, 0.63; 95% CI, 0.44-0.90) and HR-HER2- (OR, 0.77; 95% CI, 0.56-1.05) compared with HR+HER2-. Inclusion of other risk-associated variants did not change these observations. Conclusions: The rs140068132 polymorphism is associated with decreased risk of breast cancer in Peruvians and is more protective against HR- and HER2+ diseases independently of other breast cancer-associated variants in the 6q25 region. Impact: These results could inform functional analyses to understand the mechanism by which rs140068132-G reduces risk of breast cancer development in a subtype-specific manner. They also illustrate the importance of including diverse individuals in genetic studies.
UR - http://www.scopus.com/inward/record.url?scp=85135596165&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-22-0069
DO - 10.1158/1055-9965.EPI-22-0069
M3 - Artículo
C2 - 35654312
AN - SCOPUS:85135596165
SN - 1055-9965
VL - 31
SP - 1602
EP - 1609
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 8 August
ER -